Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation

NCT07656376 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

465

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer
Pancreatic Carcinoma

Interventions

DRUG: DN022150+AG( Stage I ）
DRUG: DN022150+AG（Stage II）
DRUG: placebo+AG（Stage II）

Sponsor

Jiangxi Kvvit Pharmaceutical Co., Ltd.